In humans, DRP1 mutation is typically lethal in the first few weeks of life, where patients present with neonatal encephalopathy, microcephaly, demyelination of brain matter, optic atrophy, epilepsy and global developmental delay (EMPF1, MIM #614388) [223,224]. The gene discussed is DNM1L; the disease is hereditary optic atrophy.